[Source: Journal of Infectious Diseases, full page: (LINK). Abstract, edited.]
Long-Term Antibody Response to Human Papillomavirus Vaccines: up to 12 Years Follow-Up in the Finnish Maternity Cohort
Hanna Artemchuk, Tiina Eriksson, Mario Poljak, Heljä-Marja Surcel, Joakim Dillner, Matti Lehtinen, Helena Faust
The Journal of Infectious Diseases, jiy545, https://doi.org/10.1093/infdis/jiy545
Published: 18 September 2018
Most cervical cancers are caused by vaccine-preventable infections with human papillomaviruses (HPV). HPV prophylactic vaccines Gardasil™ and Cervarix™ have been widely used for >10 years and are reported to induce high antibody levels. A head-to-head comparison of the antibody responses induced by the two vaccines has been performed only up to 5 years.
Virtually all 3,300 16- to 17-year-old Finnish females, who got one of the two HPV vaccines in phase III licensure trials, consented to registry-based long-term follow-up. Linkage with the Finnish Maternity Cohort found that they donated >2,500 serum samples up to 12 years later. Sera of 337 (38.6%) Gardasil™ and 730 (30.3%) Cervarix™ vaccine recipients were retrieved and HPV type-specific antibody levels were determined using in-house multiplexed heparin-HPV Pseudovirion Luminex assay.
HPV16 and HPV18 antibody levels remained stable and above natural infection-related antibody levels for up to 12 years for most vaccine recipients. The median antibody levels were higher among Cervarix™ recipients 7 to 12 years post vaccination (p<0.0001).
The stability of vaccine-induced antibody levels is in accordance with the high long-term protection reported previously. The differences in antibody levels induced by the two vaccines imply that continued follow-up to identify possible breakthrough cases and estimation of the minimal protective levels of serum antibodies is a research priority.
Human papillomavirus (HPV), HPV vaccine, long-term follow-up, comparison, antibodies, serology, Gardasil™, Cervarix™, Finnish Maternity Cohort (FMC)
Issue Section: Major Article
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: email@example.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
Keywords: HPV; Cancer; Vaccines; Finland.